National brain tumour research funding needs to increase to £35 million a year
APPG inquiry takes evidence from Pharma
The All-Party Parliamentary Group on Brain Tumours (APPGBT) held a fifth oral evidence session today as part of its ongoing inquiry, Pathway to a Cure – breaking down the barriers.
The witnesses today represented the pharmaceutical industry and were Northwest Biotherapeutics, QV Bioelectronics, Extruded Pharmaceuticals and Oncologica. Areas of expertise and discussion were immunotherapy, drug delivery, genomics and an implantable electric field device for the treatment of glioblastoma and other brain tumours.
The roles of Government, the NHS and Universities were scrutinised in a lively session that gave panel members much to ponder and led to a series of recommendations that are likely to form part of the inquiry report that will be delivered early in 2023.
The next oral evidence session for the APPGBT inquiry will be in June, when charity funding for brain tumour research will come under the spotlight.
If you found this story interesting or helpful, sign up to our weekly e-news and keep up to date with all the latest from Brain Tumour Research.